1525P Nab-paclitaxel/gemcitabine with or Without Epigenetic Targeting Followed by Consolidating Immune Targeting with Durvalumab and Lenalidomide in Patients with Advanced Pancreatic Ductal Adenocarcinoma: Results from the SEPION/AIO-PAK-0118 Phase I/II Study